{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:39:27Z","timestamp":1776757167452,"version":"3.51.2"},"reference-count":109,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"DOI":"10.3389\/fpubh.2020.509714","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T06:48:45Z","timestamp":1603954125000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer"],"prefix":"10.3389","volume":"8","author":[{"given":"Veronica C.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric C.","family":"Dietze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tijana","family":"Jovanovic-Talisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannine S.","family":"McCune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria L.","family":"Seewaldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and bowel project P-1 study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and bowel project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J Natl Cancer Inst."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","article-title":"Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data","volume":"381","author":"Cuzick","year":"2013","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","article-title":"Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial","volume":"352","author":"Powles","year":"1998","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/jnci\/djk050","article-title":"Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial","volume":"99","author":"Powles","year":"2007","journal-title":"J Natl Cancer Inst."},{"key":"B6","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/jnci\/djk049","article-title":"Long-term results of tamoxifen prophylaxis for breast cancer\u221296-month follow-up of the randomized IBIS-I trial","volume":"99","author":"Cuzick","year":"2007","journal-title":"J Natl Cancer Inst."},{"key":"B8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0140-6736(98)04394-3","article-title":"Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention study","volume":"352","author":"Veronesi","year":"1998","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/jnci\/djk154","article-title":"Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen prevention trial among women with hysterectomy","volume":"99","author":"Veronesi","year":"2007","journal-title":"J Natl Cancer Inst."},{"key":"B10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1370\/afm.284","article-title":"Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump","volume":"3","author":"Taylor","year":"2005","journal-title":"Ann Fam Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/bjc.2014.109","article-title":"Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic","volume":"110","author":"Donnelly","year":"2014","journal-title":"Br J Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","article-title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial","volume":"16","author":"Cuzick","year":"2015","journal-title":"Lancet Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMc1502618","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"E276","DOI":"10.1503\/cmaj.141627","article-title":"Primary chemoprevention of breast cancer: are the adverse effects too burdensome?","volume":"187","author":"Prasad","year":"2015","journal-title":"CMAJ."},{"key":"B15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10549-012-2085-6","article-title":"Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer","volume":"134","author":"Sestak","year":"2012","journal-title":"Breast Cancer Res Treat."},{"key":"B16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.tox.2013.07.014","article-title":"Evaluation of the genotoxicity of tamoxifen in the liver and kidney of F344 gpt delta transgenic rat in 3-week and 13-week repeated dose studies","volume":"312","author":"Kawamura","year":"2013","journal-title":"Toxicology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jnci\/djs125","article-title":"CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial","volume":"104","author":"Regan","year":"2012","journal-title":"J Natl Cancer Inst."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","article-title":"Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial","volume":"395","author":"Cuzick","year":"2020","journal-title":"Lancet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"740","DOI":"10.7326\/M15-2650","article-title":"Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis","volume":"164","author":"Maruthur","year":"2016","journal-title":"Ann Intern Med."},{"key":"B22","volume-title":"Clinical Obesity in Adults and Children","author":"Wilding","year":"2008"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.metabol.2013.06.006","article-title":"Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review","volume":"62","author":"Lautatzis","year":"2013","journal-title":"Metabolism."},{"key":"B24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/apha.12644","article-title":"Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium","volume":"219","author":"Triggle","year":"2017","journal-title":"Acta Physiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.2337\/dc10-2361","article-title":"Use of metformin in the setting of mild-to-moderate renal insufficiency","volume":"34","author":"Lipska","year":"2011","journal-title":"Diabetes Care."},{"key":"B26","doi-asserted-by":"publisher","first-page":"6156","DOI":"10.1038\/s41598-019-42531-0","article-title":"Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport","volume":"9","author":"Horakova","year":"2019","journal-title":"Sci Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00125-017-4361-9","article-title":"Metformin for diabetes prevention: insights gained from the diabetes prevention program\/diabetes prevention program outcomes study","volume":"60","author":"Aroda","year":"2017","journal-title":"Diabetologia."},{"key":"B28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1210\/jc.2008-0772","article-title":"Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions","volume":"93","author":"Ratner","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"B30","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.2337\/dc20-S003","article-title":"3. Prevention or delay of type 2 Diabetes: standards of medical care in Diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care."},{"key":"B31","doi-asserted-by":"publisher","first-page":"33743","DOI":"10.1038\/srep33743","article-title":"Systematic review with network meta-analysis: antidiabetic medication and risk of hepatocellular carcinoma","volume":"6","author":"Zhou","year":"2016","journal-title":"Sci Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3389\/fendo.2019.00617","article-title":"The potential effect of metformin on cancer: an umbrella review","volume":"10","author":"Yu","year":"2019","journal-title":"Front Endocrinol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"108232","DOI":"10.1016\/j.diabres.2020.108232","article-title":"Use of metformin and risk of breast and colorectal cancer","volume":"165","author":"Rennert","year":"2020","journal-title":"Diabetes Res Clin Pract."},{"key":"B34","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3816\/CBC.2008.n.060","article-title":"Insulin-lowering effects of metformin in women with early breast cancer","volume":"8","author":"Goodwin","year":"2008","journal-title":"Clin Breast Cancer."},{"key":"B35","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1158\/1940-6207.CAPR-13-0424","article-title":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","volume":"7","author":"Gandini","year":"2014","journal-title":"Cancer Prev Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/obr.12358","article-title":"Why are there race\/ethnic differences in adult body mass index-adiposity relationships? A quantitative critical review","volume":"17","author":"Heymsfield","year":"2016","journal-title":"Obes Rev"},{"key":"B37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/metabo10020048","article-title":"Metabolically healthy obesity-heterogeneity in definitions and unconventional factors","volume":"10","author":"Brandao","year":"2020","journal-title":"Metabolites."},{"key":"B38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00592-015-0756-6","article-title":"Association of diabetes and diabetes treatment with incidence of breast cancer","volume":"53","author":"Garcia-Esquinas","year":"2016","journal-title":"Acta Diabetol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10549-007-9632-6","article-title":"Epidemiology of basal-like breast cancer","volume":"109","author":"Millikan","year":"2008","journal-title":"Breast Cancer Res Treat."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1002\/cncr.25961","article-title":"Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity","volume":"117","author":"Lara-Medina","year":"2011","journal-title":"Cancer."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1158\/1055-9965.EPI-19-0291","article-title":"Relationship between diabetes and diabetes medications and risk of different molecular subtypes of breast cancer","volume":"28","author":"Chen","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3389\/fendo.2020.00058","article-title":"Metabolic health, insulin, and breast cancer: why oncologists should care about insulin","volume":"20","author":"Yee","year":"2020","journal-title":"Front Endocinol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin Pharmacokinet."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.2337\/db13-1367","article-title":"Metformin pharmacogenomics: current status and future directions","volume":"63","author":"Pawlyk","year":"2014","journal-title":"Diabetes."},{"key":"B45","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1097\/FPC.0b013e3283559b22","article-title":"Metformin pathways: pharmacokinetics and pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharmacogenet Genomics."},{"key":"B46","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/cpt.701","article-title":"Genetic polymorphisms in organic cation transporter 1 attenuates hepatic metformin exposure in humans","volume":"102","author":"Sundelin","year":"2017","journal-title":"Clin Pharmacol Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.2337\/db10-0543","article-title":"Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program","volume":"59","author":"Jablonski","year":"2010","journal-title":"Diabetes."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1172\/JCI30558","article-title":"Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action","volume":"117","author":"Shu","year":"2007","journal-title":"J Clin Invest."},{"key":"B49","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/sj.clpt.6100275","article-title":"Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics","volume":"83","author":"Shu","year":"2008","journal-title":"Clin Pharmacol Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/tpj.2009.15","article-title":"Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus","volume":"9","author":"Becker","year":"2009","journal-title":"Pharmacogenomics J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/FPC.0b013e32834c0010","article-title":"The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c","volume":"21","author":"Christensen","year":"2011","journal-title":"Pharmacogenet Genomics."},{"key":"B52","doi-asserted-by":"publisher","first-page":"E204","DOI":"10.1210\/jc.2010-0145","article-title":"Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome","volume":"95","author":"Gambineri","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"B53","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10038-006-0087-0","article-title":"Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin","volume":"52","author":"Shikata","year":"2007","journal-title":"J Hum Genet."},{"key":"B54","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/clpt.2009.92","article-title":"The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin","volume":"86","author":"Tzvetkov","year":"2009","journal-title":"Clin Pharmacol Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/clpt.2012.210","article-title":"The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin","volume":"93","author":"Stocker","year":"2013","journal-title":"Clin Pharmacol Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/clpt.2011.165","article-title":"A common 5\u2032-UTR variant in MATE2-K is associated with poor response to metformin","volume":"90","author":"Choi","year":"2011","journal-title":"Clin Pharmacol Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/j.1440-1681.2011.05610.x","article-title":"Serine racemase rs391300 G\/A polymorphism influences the therapeutic efficacy of metformin in Chinese patients with diabetes mellitus type 2","volume":"38","author":"Dong","year":"2011","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00125-012-2537-x","article-title":"A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts","volume":"55","author":"van Leeuwen","year":"2012","journal-title":"Diabetologia."},{"key":"B59","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/ng.735","article-title":"Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes","volume":"43","author":"Zhou","year":"2011","journal-title":"Nat Genet."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2217\/pgs.12.115","article-title":"Replication of the association of gene variant near ATM and response to metformin","volume":"13","author":"Tkac","year":"2012","journal-title":"Pharmacogenomics."},{"key":"B61","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1210\/jc.2008-1994","article-title":"Impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women: do we need a new drug?","volume":"93","author":"Legro","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e3109","DOI":"10.1002\/dmrr.3109","article-title":"Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine","volume":"35","author":"Mannino","year":"2019","journal-title":"Diabetes Metab Res Rev."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e0165214","DOI":"10.1371\/journal.pone.0165214","article-title":"MATE2 expression is associated with cancer cell response to metformin","volume":"11","author":"Chowdhury","year":"2016","journal-title":"PLoS ONE."},{"key":"B64","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1053\/j.seminoncol.2015.09.009","article-title":"Repurposing old drugs to chemoprevention: the case of metformin","volume":"43","author":"Heckman-Stoddard","year":"2016","journal-title":"Semin Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature13270","article-title":"Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase","volume":"510","author":"Madiraju","year":"2014","journal-title":"Nature."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1126\/science.1120781","article-title":"The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin","volume":"310","author":"Shaw","year":"2005","journal-title":"Science."},{"key":"B67","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cmet.2006.05.005","article-title":"Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome","volume":"3","author":"Cool","year":"2006","journal-title":"Cell Metab."},{"key":"B68","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1172\/JCI27300","article-title":"Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2","volume":"116","author":"Savage","year":"2006","journal-title":"J Clin Invest."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/nm.3372","article-title":"Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin","volume":"19","author":"Fullerton","year":"2013","journal-title":"Nat Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1053\/j.gastro.2006.07.032","article-title":"Neither LKB1 nor AMPK are the direct targets of metformin","volume":"131","author":"Hardie","year":"2006","journal-title":"Gastroenterology."},{"key":"B71","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","article-title":"Metformin: from mechanisms of action to therapies","volume":"20","author":"Foretz","year":"2014","journal-title":"Cell Metab."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1038\/s41375-019-0470-4","article-title":"Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells","volume":"33","author":"Mishra","year":"2019","journal-title":"Leukemia."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/cas.13523","article-title":"Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma","volume":"109","author":"Sekino","year":"2018","journal-title":"Cancer Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","article-title":"Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission","volume":"69","author":"Hirsch","year":"2009","journal-title":"Cancer Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.semcdb.2019.05.010","article-title":"The multifaceted effects of metformin on tumor microenvironment","volume":"98","author":"Kurelac","year":"2020","journal-title":"Semin Cell Dev Biol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.3892\/or.2018.6751","article-title":"Metformin suppresses hypoxiainduced migration via the HIF1alpha\/VEGF pathway in gallbladder cancer in vitro and in vivo","volume":"40","author":"Ye","year":"2018","journal-title":"Oncol Rep."},{"key":"B77","doi-asserted-by":"publisher","first-page":"44579","DOI":"10.18632\/oncotarget.6373","article-title":"Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2\/HIF-1alpha\/VEGF secretion axis","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget."},{"key":"B78","doi-asserted-by":"publisher","first-page":"5622","DOI":"10.1158\/1078-0432.CCR-18-0420","article-title":"Metformin inhibits prostate cancer progression by targeting tumor-associated inflammatory infiltration","volume":"24","author":"Liu","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1158\/1078-0432.CCR-15-1839","article-title":"PlGF\/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity","volume":"22","author":"Incio","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/2326-6066.CIR-16-0103","article-title":"Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia","volume":"5","author":"Scharping","year":"2017","journal-title":"Cancer Immunol Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1158\/0008-5472.CAN-17-2460","article-title":"Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer","volume":"78","author":"Li","year":"2018","journal-title":"Cancer Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.jid.2017.03.033","article-title":"phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma","volume":"137","author":"Kim","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin\u2013mode of action and clinical implications for diabetes and cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat Rev Endocrinol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ctrv.2016.03.004","article-title":"New insights on PI3K\/AKT pathway alterations and clinical outcomes in breast cancer","volume":"45","author":"Yang","year":"2016","journal-title":"Cancer Treat Rev."},{"key":"B85","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1002\/jcb.26687","article-title":"The prognostic value of PI3K mutational status in breast cancer: a meta-analysis","volume":"119","author":"Sobhani","year":"2018","journal-title":"J Cell Biochem."},{"key":"B86","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/jnci\/djs648","article-title":"PKB\/Akt-dependent regulation of cell motility","volume":"105","author":"Xue","year":"2013","journal-title":"J Natl Cancer Inst."},{"key":"B87","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat Rev Cancer."},{"key":"B88","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.semcancer.2008.11.010","article-title":"Is Akt the \u201cWarburg kinase\u201d?","volume":"19","author":"Robey","year":"2009","journal-title":"Semin Cancer Biol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s12094-019-02187-8","article-title":"Emerging roles of aerobic glycolysis in breast cancer","volume":"22","author":"Wu","year":"2020","journal-title":"Clin Transl Oncol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-3-319-42118-6_3","article-title":"Metabolic reprogramming by the PI3K-Akt-mTOR pathway in Cancer","volume":"207","author":"Lien","year":"2016","journal-title":"Recent Results Cancer Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1046\/j.1524-4741.2001.21570.x","article-title":"Chemoprevention for high-risk women: tamoxifen and beyond","volume":"7","author":"Fabian","year":"2001","journal-title":"Breast J."},{"key":"B92","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4172\/2161-1041.1000104","article-title":"Metformin- a promising agent for chemoprevention in BRCA1 carriers","volume":"1","author":"Kumar","year":"2012","journal-title":"Hereditary Genet."},{"key":"B93","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1210\/en.2003-0982","article-title":"Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status","volume":"144","author":"Hardie","year":"2003","journal-title":"Endocrinology."},{"key":"B94","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.tips.2015.11.007","article-title":"Evolving lessons on the complex role of AMPK in normal physiology and cancer","volume":"37","author":"Dasgupta","year":"2016","journal-title":"Trends Pharmacol Sci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"52974","DOI":"10.18632\/oncotarget.9732","article-title":"Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based \u201cstarvation\u201d strategies in BRCA1 carriers","volume":"7","author":"Cuyas","year":"2016","journal-title":"Oncotarget."},{"key":"B96","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10549-011-1612-1","article-title":"Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial","volume":"128","author":"Hadad","year":"2011","journal-title":"Breast Cancer Res Treat."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1200\/JCO.2011.39.3769","article-title":"Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial","volume":"30","author":"Bonanni","year":"2012","journal-title":"J Clin Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3109\/07357907.2014.889706","article-title":"Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer","volume":"32","author":"Kalinsky","year":"2014","journal-title":"Cancer Invest."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1200\/JCO.2012.42.3293","article-title":"Cracking open window of opportunity trials","volume":"30","author":"Kalinsky","year":"2012","journal-title":"J Clin Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s10549-012-2223-1","article-title":"Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study","volume":"135","author":"Niraula","year":"2012","journal-title":"Breast Cancer Res Treat."},{"key":"B101","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00280-012-1977-9","article-title":"Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer","volume":"71","author":"Esteva","year":"2013","journal-title":"Cancer Chemother Pharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"djv006","DOI":"10.1093\/jnci\/djv006","article-title":"Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32","volume":"107","author":"Goodwin","year":"2015","journal-title":"J Natl Cancer Inst."},{"key":"B103","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.breast.2019.08.003","article-title":"A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy","volume":"48","author":"Pimentel","year":"2019","journal-title":"Breast."},{"key":"B104","doi-asserted-by":"publisher","first-page":"TPS11628","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS11628","article-title":"A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors","volume":"35","author":"Sehdev","year":"2017","journal-title":"J Clin Oncol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.clbc.2012.03.004","article-title":"Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study","volume":"12","author":"Campagnoli","year":"2012","journal-title":"Clin Breast Cancer."},{"key":"B106","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1200\/JCO.2011.35.2237","article-title":"Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer","volume":"30","author":"Macis","year":"2012","journal-title":"J Clin Oncol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1038\/bjc.2013.657","article-title":"The effect of metformin on apoptosis in a breast cancer presurgical trial","volume":"109","author":"Cazzaniga","year":"2013","journal-title":"Br J Cancer."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/jnci\/djy040","article-title":"The effects of metformin and weight loss on biomarkers associated with breast cancer outcomes","volume":"110","author":"Patterson","year":"2018","journal-title":"J Natl Cancer Inst."},{"key":"B109","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/s12885-016-2551-3","article-title":"Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol","volume":"16","author":"Martinez","year":"2016","journal-title":"BMC Cancer."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2020.509714\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T06:48:48Z","timestamp":1603954128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2020.509714\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":109,"alternative-id":["10.3389\/fpubh.2020.509714"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2020.509714","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"article-number":"509714"}}